Conversion of Olmesartan to Olmesartan Medoxomil, A Prodrug that Improves Intestinal Absorption, Confers Substrate Recognition by OATP2B1
CONCLUSION: Olmesartan-MX is a substrate for OATP2B1, and the naringin-sensitive transport system contributes to the improved intestinal absorption of olmesartan-MX compared with its parent drug, olmesartan.PMID:38485855 | DOI:10.1007/s11095-024-03687-1 (Source: Cell Research)
Source: Cell Research - March 15, 2024 Category: Cytology Authors: Naomi Fukazawa Tomohiro Nishimura Keisuke Orii Saki Noguchi Masatoshi Tomi Source Type: research
Conversion of Olmesartan to Olmesartan Medoxomil, A Prodrug that Improves Intestinal Absorption, Confers Substrate Recognition by OATP2B1
ConclusionOlmesartan-MX is a substrate for OATP2B1, and the naringin-sensitive transport system contributes to the improved intestinal absorption of olmesartan-MX compared with its parent drug, olmesartan. (Source: Pharmaceutical Research)
Source: Pharmaceutical Research - March 14, 2024 Category: Drugs & Pharmacology Source Type: research
Olmesartan-medoxomil
(Source: Reactions Weekly)
Source: Reactions Weekly - March 1, 2024 Category: Drugs & Pharmacology Source Type: research
Efficacy and safety of olmesartan medoxomil ‑amlodipine besylate tablets (Sevikar < sup > ® < /sup > ) in older patients with essential hypertension: Subgroup analysis from the Sevikar study
In conclusion, OM-AML tablets may be considered effective and safe in lowering BP, enabling the achievement of guideline-recommended BP targets in older Chinese patients with essential hypertension.PMID:38234624 | PMC:PMC10790165 | DOI:10.3892/etm.2023.12338 (Source: Experimental and Therapeutic Medicine)
Source: Experimental and Therapeutic Medicine - January 18, 2024 Category: General Medicine Authors: Zhaoqiang Cui Zhaohui Qiu Wenli Cheng Wei Hu Genshan Ma Xiaojun Cai Yafei Jin Yi Zhao Liqun He Ying Li Peili Bu Xiaoping Chen Ruxing Wang Lin Chen Peng Dong Liuliu Feng Xuebin Han Mei Hong Yinglong Hou Minlei Liao Mingliang Wang Xiaoyan Wang Jianhong Xie Source Type: research
The Efficacy of Single-pill Combination of Olmesartan Medoxomil and Amlodipine Besylate on Office Blood Pressure in Hypertensive Patients who did not Respond to Amlodipine Besylate Monotherapy
CONCLUSION: SPC (OLM 20 mg/AML 5 mg) treatment for 8 weeks was effective in reducing BP, achieving target BP goal, and also improving arterial stiffness in uncontrolled hypertensive patients with AML 5 mg monotherapy.PMID:38152599 | PMC:PMC10751208 | DOI:10.5049/EBP.2023.21.2.45 (Source: Electrolyte and Blood Pressure)
Source: Electrolyte and Blood Pressure - December 28, 2023 Category: Internal Medicine Authors: Byong-Kyu Kim Source Type: research
